title: Reply to Johnson.
authors.affiliation: Justus-Liebig University, Giessen, Germany; wagenlehner@aol.com.
authors.forename: Florian M
authors.initials: FM
authors.lastname: Wagenlehner
authors.affiliation: AstraZeneca, Alderley Park, Cheshire, United Kingdom.
authors.forename: Paul
authors.initials: P
authors.lastname: Newell
authors.affiliation: AstraZeneca, Alderley Park, Cheshire, United Kingdom.
authors.forename: Katrina
authors.initials: K
authors.lastname: Yates
authors.affiliation: AstraZeneca, Wilmington, Delaware.
authors.forename: Leanne B
authors.initials: LB
authors.lastname: Gasink
mesh_terms: D053961:Azabicyclo Compounds; D002442:Ceftazidime; D000077726:Doripenem; D004338:Drug Combinations; D006801:Humans; D011704:Pyelonephritis; D014552:Urinary Tract Infections
chemical_list: D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D002442:Ceftazidime; D000077726:Doripenem